- The FRAMES Clinical Study in FRDA
The FRAMES trial was a phase 2 randomized, double-blind, placebo-controlled, clinical study that was designed to assess the efficacy and safety of leriglitazone in patients with Friedreich's ataxia (FRDA) with input from EU and US clinical experts and patient advocacy groups.
The study recruited 36 patients and results showed clinical benefit on this population.
Preclinical data showing potential therapeutic action and protection against neurodegenaration, in particular againts Friedereich's Ataxia, was published in Neurobiology of Disease: PPAR gamma agonist leriglitazone improves frataxin-loss impairments in cellular and animal models of Friedreich Ataxia - ScienceDirect
For further information visit:
https://clinicaltrials.gov/ct2/show/NCT03917225?term=MIN102&rank=2Hospitals involved in FRAMES Clinical StudySee mapHôpital Erasme-ULBBrusselsBelgiumICM, Groupe Hospitalier Pitié SalpêtrièreParisFranceRWTH Aachen UniversityAachenGermanyHospital Universitario La PazMadridSpainHospital Sant Joan de DéuBarcelonaSpainHospitals involved in FRAMES Clinical StudySee listHôpital Erasme-ULBBrusselsBelgiumICM, Groupe Hospitalier Pitié SalpêtrièreParisFranceRWTH Aachen UniversityAachenGermanyHospital Universitario La PazMadridSpainHospital Sant Joan de DéuBarcelonaSpain